Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

This bill modifies the rules for Minnesota's Formulary Committee, which decides which prescription drugs are covered by state medical assistance programs. It allows committee members who have potential conflicts of interest to still attend meetings and discuss issues, provided they disclose these interests and step away from specific votes where a conflict exists. The legislation also mandates that the committee seek expert input from the Minnesota Rare Disease Advisory Council before making decisions on prior authorization requirements or placing orphan drugs on preferred lists. Additionally, the bill requires the commissioner of human services to create a public process for receiving comments on the committee's recommendations and sets specific criteria for committee membership and compensation.